You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 59 No. 6, June 2002 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (46)
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in this journal
 Topic Collections
 •HIV/AIDS
 •Immunologic Disorders
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Progression to Neuropsychological Impairment in Human Immunodeficiency Virus Infection Predicted by Elevated Cerebrospinal Fluid Levels of Human Immunodeficiency Virus RNA

Ronald J. Ellis, MD, PhD; David J. Moore, BS; Meredith E. Childers, MA; Scott Letendre, MD; J. Allen McCutchan, MD; Tanya Wolfson, MA; Stephen A. Spector, MD; Karen Hsia, PhD; Robert K. Heaton, PhD; Igor Grant, MD; for the HNRC Group

Arch Neurol. 2002;59:923-928.

Background  If cerebrospinal fluid (CSF) human immunodeficiency virus (HIV) RNA levels are elevated before the development of neuropsychological (NP) impairment, such an observation would support prospective monitoring of CSF HIV RNA levels as well as therapeutic interventions designed to lower CSF HIV levels.

Objective  To determine whether increased CSF HIV RNA levels at an earlier time predict subsequent progression to NP impairment in HIV-infected subjects.

Methods  We examined 139 subjects in a prospective cohort study. Comprehensive NP, neuromedical, and laboratory evaluations were performed at initial and follow-up visits at least 6 months apart. Human immunodeficiency virus RNA levels in plasma and CSF were measured with a commercially available, polymerase chain reaction–based assay. To assess the robustness of our findings, we analyzed changes in NP performance over time in 2 ways. First, we used masked clinical ratings of global NP performance to identify individuals who were initially NP normal, and then determined, in a similarly blinded fashion, which of these subjects subsequently became NP impaired. Second, in a separate analysis, we assessed change in subjects' raw scores on each of a series of NP test measures between baseline and follow-up.

Results  Among subjects who were not impaired at the initial visit, higher levels of HIV RNA in CSF significantly predicted progression to global NP impairment at the follow-up evaluation. Cerebrospinal fluid HIV RNA levels outperformed other clinical and laboratory measures in predicting progression to NP impairment. Higher CSF HIV RNA levels were associated with worsening performance on tests of attention, learning, and motor function.

Conclusion  Because elevated CSF HIV RNA levels (>=200 copies/mL) predict subsequent progression to NP impairment, monitoring of CSF viral load and therapy to reduce CSF HIV RNA levels may be clinically warranted, even if impairment is not identified at the time of lumbar puncture.


From the Department of Neurosciences (Dr Ellis and Ms Childers), HIV Neurobehavioral Research Center (HNRC) (Drs Ellis, Letendre, McCutchan, Heaton, and Grant, Mr Moore, and Mss Childers and Wolfson), and Departments of Psychiatry (Mr Moore and Drs Heaton and Grant), Medicine (Drs Letendre and McCutchan), and Pediatrics (Drs Spector and Hsia), University of California, San Diego (UCSD); San Diego State University/UCSD Joint Doctoral Program in Clinical Psychology (Mr Moore); and Veterans Affairs Healthcare System (Dr Grant), San Diego. The San Diego HNRC Group is affiliated with the University of California, San Diego, the Naval Hospital, San Diego, and the San Diego Veterans Affairs Healthcare System.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2002;59(6):1048-1050.
FULL TEXT  

Through a Glass, Darkly: Cerebrospinal Fluid Viral Load Measurements and the Pathogenesis of Human Immunodeficiency Virus Infection of the Central Nervous System
Kenneth L. Tyler and Justin C. McArthur
Arch Neurol. 2002;59(6):909-912.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Compartmentalized Human Immunodeficiency Virus Type 1 Present in Cerebrospinal Fluid Is Produced by Short-Lived Cells
Harrington et al.
J. Virol. 2005;79:7959-7966.
ABSTRACT | FULL TEXT  

Genetic Composition of Human Immunodeficiency Virus Type 1 in Cerebrospinal Fluid and Blood without Treatment and during Failing Antiretroviral Therapy
Strain et al.
J. Virol. 2005;79:1772-1788.
ABSTRACT | FULL TEXT  

Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia
Sevigny et al.
Neurology 2004;63:2084-2090.
ABSTRACT | FULL TEXT  

Attenuated Central Nervous System Infection in Advanced HIV/AIDS With Combination Antiretroviral Therapy
McArthur et al.
Arch Neurol 2004;61:1687-1696.
ABSTRACT | FULL TEXT  

Prediction of Incident Neurocognitive Impairment by Plasma HIV RNA and CD4 Levels Early After HIV Seroconversion
Marcotte et al.
Arch Neurol 2003;60:1406-1412.
ABSTRACT | FULL TEXT  

Response to systemic HIV viral load suppression correlates with psychomotor speed performance
Sacktor et al.
Neurology 2003;61:567-569.
ABSTRACT | FULL TEXT  

Through a Glass, Darkly: Cerebrospinal Fluid Viral Load Measurements and the Pathogenesis of Human Immunodeficiency Virus Infection of the Central Nervous System
Tyler and McArthur
Arch Neurol 2002;59:909-912.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2002 American Medical Association. All Rights Reserved.